Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD

NCT01414153 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

Exudative Age-related Macular Degeneration

Interventions

DRUG: 4.0 mg iSONEP
DRUG: 0.5 mg iSONEP
DRUG: 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
DRUG: sham injection

Sponsor

Lpath, Inc.